Artiva Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- $248.6M
- Website
- http://www.artivabio.com
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Phase 2
Recruiting
- Conditions
- Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)Systemic Sclerosis (SSc)Rheumatoid Arthritis (RAIIMMyositisSclerodermaSjogren SyndromeSjogrens Disease
- Interventions
- Drug: Allogeneic NK Cells
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06991114
- Locations
- 🇺🇸
Artiva Clinical Trial Site, Houston, Texas, United States
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Phase 1
Recruiting
- Conditions
- SLELupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVRefractory Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06265220
- Locations
- 🇺🇸
Artiva Clinical Trial Site, The Woodlands, Texas, United States
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT05678205
- Locations
- 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
Artiva Clinical Trial Site, Richmond, Virginia, United States